Silk Road Medical, Inc (SILK)
- Previous Close
17.41 - Open
17.39 - Bid 17.68 x 100
- Ask 17.85 x 100
- Day's Range
17.34 - 18.06 - 52 Week Range
6.08 - 45.41 - Volume
165,468 - Avg. Volume
753,677 - Market Cap (intraday)
696.133M - Beta (5Y Monthly) 1.48
- PE Ratio (TTM)
-- - EPS (TTM)
-1.44 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.17
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
silkroadmed.comRecent News: SILK
Performance Overview: SILK
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SILK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SILK
Valuation Measures
Market Cap
682.81M
Enterprise Value
578.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.82
Price/Book (mrq)
4.52
Enterprise Value/Revenue
3.27
Enterprise Value/EBITDA
-12.84
Financial Highlights
Profitability and Income Statement
Profit Margin
-31.47%
Return on Assets (ttm)
-13.85%
Return on Equity (ttm)
-35.39%
Revenue (ttm)
177.13M
Net Income Avi to Common (ttm)
-55.74M
Diluted EPS (ttm)
-1.44
Balance Sheet and Cash Flow
Total Cash (mrq)
181.47M
Total Debt/Equity (mrq)
55.99%
Levered Free Cash Flow (ttm)
-12.13M
Research Analysis: SILK
Company Insights: SILK
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: SILK
Weekly Stock List
The first quarter of 2024 was rewarding for equity investors, as the S&P 500 increased 10.2%. Much of the market participated, as the S&P 500 Growth Index advanced 12.6% and the S&P 500 Value Index rose 7.4%. Leading sectors included Communication Services (+15.6%), Energy (+12.7%), Technology (+12.5%), Financials (+12%), and Industrials (+10.6%). The average stock in the Argus Universe of Coverage rose 8.0% during the year, and the median stock advanced 7.2%. The average BUY-rated stock increased 9.9%, while the average HOLD-rated stock gained 3%. Will the market's breadth hold up for the balance of 2024 or will investors revert to the so-called Magnificent 7? Will small-caps pick up their pace (the Russell 2000 was up "only" 4.8% in 1Q) or is the current bull-market rally due for a break, with some profit-taking coming into play? Given declining interest rates, we expect growth stocks to continue to lead stocks higher, while the risk of recession puts a premium on clean balance sheets, which are also more prevalent among large-caps. Investors seeking value are encouraged to focus on dividends and look for yields in the 3%-4% range. Here are the Top 10 Performers from the Argus Universe last quarter (including representatives of six of the 11 major sectors) as well as the Bottom-Five Performers.
The Argus Mid-Cap Model Portfolio
Small- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.
Analyst Report: Silk Road Medical Inc
Based in Sunnyvale, California, Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR combines the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages that may cause strokes.
RatingPrice TargetMarket Digest: ADSK, KO, PSA, SILK, KVUE
Rallying Market Ignores Warning Signs: Our Monthly Survey of the Economy, Interest Rates, and Stocks